C Ray Therapeutics

About C Ray Therapeutics

C Ray Therapeutics, established in 2021, is a biopharmaceutical company specializing in radiopharmaceuticals. Based in Chengdu, China, the firm was incubated by the venture capital firm 6 Dimensions Capital. C Ray is dedicated to the development, manufacturing, and clinical application of radiopharmaceuticals, which are specialized drugs that incorporate radioactive isotopes to diagnose and treat diseases, particularly in oncology, cardiovascular diseases, and neurological disorders.

The company operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing end-to-end services to a global client base. Its business model revolves around offering a comprehensive suite of services that cover the entire lifecycle of radiopharmaceutical development. This includes process development, quality research, preclinical evaluation, Investigational New Drug (IND) enabling studies, clinical supply, and commercial-scale cGMP production. By providing these integrated services, C Ray helps partners navigate the complexities of drug development, from early discovery and preclinical research to clinical trials and commercial manufacturing. The company has successfully managed 50 CRDMO projects, with several advancing to IND-enabling stages, investigator-initiated trials (IITs), and even a Phase III clinical study.

A key aspect of C Ray's operations is its advanced R&D and production infrastructure. The company has constructed a nearly 30,000-square-meter facility in Chengdu Medical City that meets global cGMP standards and holds a Class A Radiation Safety License in China. This allows for the handling of over 30 different radionuclides. C Ray can independently produce diagnostic imaging nuclides like Cu-64, Ga-68, Zr-89, and F-18. These are used to label molecules for preclinical animal imaging, biodistribution studies, and clinical imaging. The company has also established a robust supply chain for critical isotopes, including the challenging Ac-225, and formed the Radiopharmaceutical Innovation Alliance with industry partners to address supply and development hurdles.